Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Mena Abaskharoun"'
Autor:
Hussein A, Tawbi, Dirk, Schadendorf, Evan J, Lipson, Paolo A, Ascierto, Luis, Matamala, Erika, Castillo Gutiérrez, Piotr, Rutkowski, Helen J, Gogas, Christopher D, Lao, Juliana Janoski, De Menezes, Stéphane, Dalle, Ana, Arance, Jean-Jacques, Grob, Shivani, Srivastava, Mena, Abaskharoun, Melissa, Hamilton, Sarah, Keidel, Katy L, Simonsen, Anne Marie, Sobiesk, Bin, Li, F Stephen, Hodi, Georgina V, Long, Sajeve, Thomas
Publikováno v:
The New England journal of medicine. 386(1)
BACKGROUND: Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination of relatlimab, a LAG-3-blocking antibody, and nivolumab, a PD-1-blocking a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0feb8c15306160d75f7490cd16650a6e
https://pubmed.ncbi.nlm.nih.gov/35544393
https://pubmed.ncbi.nlm.nih.gov/35544393
Autor:
Jean-Jacques Grob, Evan J. Lipson, Bin Li, Erika Castillo Gutiérrez, Georgina V. Long, Shivani Srivastava, F. Stephen Hodi, Hussein Abdul-Hassan Tawbi, Helen Gogas, Piotr Rutkowski, Paolo A. Ascierto, Luis Matamala, Christopher D. Lao, Juliana Janoski de Menezes, Stéphane Dalle, Katy L. Simonsen, Mena Abaskharoun, Ana Arance, Dirk Schadendorf
9503 Background: Immune checkpoint inhibitor therapy has revolutionized the treatment of patients with advanced melanoma. However, novel combinations are needed to optimize the benefit-risk profile. Lymphocyte-activation gene 3 (LAG-3) regulates an i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::494b7104d9f2fb0f144b6df66dbffe5c
Autor:
Andreas Hochhaus, Jorge E. Cortes, Neil P. Shah, Michael J. Mauro, Mena Abaskharoun, Oumar Sy, Giuseppe Saglio, Ehab Atallah
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 17:S14-S15
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::06979d400c7aa595b1f1ea45fa09d6b0
https://doi.org/10.1016/j.clml.2017.09.042
https://doi.org/10.1016/j.clml.2017.09.042
Autor:
Ehab Atallah, Jorge E. Cortes, Oumar Sy, Michael J. Mauro, Neil P. Shah, Mena Abaskharoun, Andreas Hochhaus, Giuseppe Saglio
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 17:S312-S313
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::73189b169b1b4a1b36b4316358546782
https://doi.org/10.1016/j.clml.2017.07.113
https://doi.org/10.1016/j.clml.2017.07.113